Determination of the composition, encapsulation efficiency and loading capacity in protein drug delivery systems using circular dichroism spectroscopy

Analytica Chimica Acta

Volumn 937, Issue , 2016, Pages 113-118

  Peng, Zhili ^a   Li, Shanghao ^a   Han, Xu ^a   Al Youbi, Abdulrahman O ^b   Bashammakh, Abdulaziz S ^b   El Shahawi, Mohammad S ^b   Leblanc, Roger M ^a  

^a Department of Biology   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Circular dichroism spectroscopy; Drug delivery; Encapsulation efficiency; Loading capacity; Peptide and protein

Indexed keywords

BIOCHEMISTRY; CARBON; CONJUGATED POLYMERS; DICHROISM; DRUG DELIVERY; EFFICIENCY; ENCAPSULATION; PEPTIDES; PROTEINS;

ANALYTICAL METHOD; DRUG CANDIDATES; DRUG DELIVERY SYSTEM; ENCAPSULATION EFFICIENCY; HUMAN SERUM ALBUMINS; LOADING CAPACITIES; MEMBRANE PERMEABILITY; PROTEIN DRUG DELIVERY;

CIRCULAR DICHROISM SPECTROSCOPY;

ALPHA 1 ANTITRYPSIN; CARBON DOT; DRUG CARRIER; GLOBULIN; HUMAN SERUM ALBUMIN; MACROGOL; POLYMER O (2 CARBOXYETHYL) POLYETHYLENEGLYCOL; R GLOBULIN; RECOMBINANT HEMOGLOBIN; TRANSFERRIN; UNCLASSIFIED DRUG; HEMOGLOBIN; SERUM ALBUMIN;

ANALYTIC METHOD; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; HUMAN; MOLECULAR WEIGHT; NANOENCAPSULATION; PRIORITY JOURNAL; CHEMISTRY;

ALPHA 1-ANTITRYPSIN; CIRCULAR DICHROISM; DRUG DELIVERY SYSTEMS; GLOBULINS; HEMOGLOBINS; HUMANS; SERUM ALBUMIN; TRANSFERRIN;

EID: 84989811858     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2016.08.014     Document Type: Article

References (35)

1. [1] Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov. Today 20 (2015), 122–128.
2. [2] Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008), 21–39.
3. [3] Craik, D.J., Fairlie, D.P., Liras, S., Price, D., The future of peptide-based drugs. Chem. Biol. Drug Des. 81 (2013), 136–147.
4. [4] Solaro, R., Chiellini, F., Battisti, A., Targeted delivery of protein drugs by nanocarriers. Materials 3 (2010), 1928–1980.
5. [5] Chung, J.E., Tan, S., Gao, S.J., Yongvongsoontorn, N., Kim, S.H., Lee, J.H., Choi, H.S., Yano, H., Zhuo, L., Kurisawa, M., Ying, J.Y., Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. Nat. Nanotechnol. 9 (2014), 907–912.
6. [6] Otvos, L., Wade, J.D., Current challenges in peptide-based drug discovery. Front. Chem. 2 (2014), 1–4.
7. [7] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13 (2014), 655–672.
8. [8] Bruno, B.J., Miller, G.D., Lim, C.S., Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4 (2013), 1443–1467.
9. [9] Ke, X.Y., Ng, V.W.L., Ono, R.J., Chan, J.M.W., Krishnamurthy, S., Wang, Y., Hedrick, J.L., Yang, Y.Y., Role of non-covalent and covalent interactions in cargo loading capacity and stability of polymeric micelles. J. Control. Release 193 (2014), 9–26.
10. [10] Allen, T.M., Cullis, P.R., Drug delivery systems: entering the mainstream. Science 303 (2004), 1818–1822.
11. [11] Zolnik, B.S., Gonzalez-Fernandez, A., Sadrieh, N., Dobrovolskaia, M.A., Minireview: nanoparticles and the immune system. Endocrinology 151 (2010), 458–465.
12. [12] Whitaker, J.R., Granum, P.E., An absolute method for protein determination based on difference in absorbance at 235 and 280 nm. Anal. Biochem. 109 (1980), 156–159.
13. [13] El-Say, K.M., Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design. Drug Des. Dev. Ther. 10 (2016), 825–839.
14. [14] Zhang, Z.P., Feng, S.S., The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27 (2006), 4025–4033.
15. [15] Sotnikov, D.V., Radchenko, A.S., Zherdev, A.V., Dzantiev, B.B., Determination of the composition and functional activity of the conjugates of colloidal gold and antibodies. Eurasian J. Anal. Chem. 11 (2016), 169–179.
16. [16] Fajzulin, I., Zhu, X.M., Moller, M., Nanoparticulate inorganic UV absorbers: a review. J. Coat. Technol. Res. 12 (2015), 617–632.
17. [17] Lohse, B., Bolinger, P.Y., Stamou, D., Encapsulation efficiency measured on single small unilamellar vesicles. J. Am. Chem. Soc. 130 (2008), 14372–14373.
18. [18] Sun, B.Y., Chiu, D.T., Determination of the encapsulation efficiency of individual vesicles using single-vesicle photolysis and confocal single-molecule detection. Anal. Chem. 77 (2005), 2770–2776.
19. [19] Li, S.H., Peng, Z.L., Leblanc, R.M., Method to determine protein concentration in the protein nanoparticle conjugates aqueous solution using circular dichroism spectroscopy. Anal. Chem. 87 (2015), 6455–6459.
20. [20] Li, S.H., Wang, L.Y., Chusuei, C.C., Suarez, V.M., Blackwelder, P.L., Micic, M., Orbulescu, J., Leblanc, R.M., Nontoxic carbon dots potently inhibit human insulin fibrillation. Chem. Mater. 27 (2015), 1764–1771.
21. [21] Haag, R., Kratz, F., Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 45 (2006), 1198–1215.
22. [22] Haag, R., Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew. Chem. Int. Ed. 43 (2004), 278–282.
23. [23] Kumari, A., Yadav, S.K., Yadav, S.C., Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75 (2010), 1–18.
24. [24] Zhang, Y., Chan, H.F., Leong, K.W., Advanced materials and processing for drug delivery: the past and the future. Adv. Drug Deliv. Rev. 65 (2013), 104–120.
25. [25] Li, S., Peng, Z., Dallman, J., Baker, J., Othman, A.M., Blackwelder, P.L., Leblanc, R.M., Crossing the blood-brain-barrier with transferrin conjugated carbon dots: a zebrafish model study. Colloids Surf. B Biointerfaces 145 (2016), 251–256.
26. [26] Lim, S.Y., Shen, W., Gao, Z.Q., Carbon quantum dots and their applications. Chem. Soc. Rev. 44 (2015), 362–381.
27. [27] Teschler, H., Long-term experience in the treatment of alpha1-antitrypsin deficiency: 25 years of augmentation therapy. Eur. Respir. Rev. 24 (2015), 46–51.
28. [28] Rachmiel, M., Strauss, P., Dror, N., Benzaquen, H., Horesh, O., Tov, N., Weintrob, N., Landau, Z., Ben-Ami, M., Haim, A., Phillip, M., Bistritzer, T., Lewis, E.C., Lebenthal, Y., Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus. Pediatr. Diabetes, 2015, 10.1111/pedi.12283.
29. [29] Schechter, A.N., Hemoglobin research and the origins of molecular medicine. Blood 112 (2008), 3927–3938.
30. [30] Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., Ascenzi, P., Human serum albumin: from bench to bedside. Mol. Asp. Med. 33 (2012), 209–290.
31. [31] Gkouvatsos, K., Papanikolaou, G., Pantopoulos, K., Regulation of iron transport and the role of transferrin. Bba General Subj. 1820 (2012), 188–202.
32. [32] Cherin, P., Piette, J.C., Wechsler, B., Bletry, O., Ziza, J.M., Laraki, R., Godeau, P., Herson, S., Intravenous gamma-globulin as first line therapy in polymyositis and dermatomyositis - an open study in 11 adult patients. J. Rheumatol. 21 (1994), 1092–1097.
33. [33] Choy, E.H.S., Isenberg, D.A., Treatment of dermatomyositis and polymyositis. Rheumatology 41 (2002), 7–13.
34. [34] Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
35. [35] Wang, S.B., Chen, A.Z., Weng, L.J., Chen, M.Y., Xie, X.L., Effect of drug-loading methods on drug load, encapsulation efficiency and release properties of alginate/poly-L-arginine/chitosan ternary complex microcapsules. Macromol. Biosci. 4 (2004), 27–30.